Business Context and Reporting Period
This Form 8-K Current Report was filed by ImmunityBio, Inc. on December 17, 2021. The report details a material definitive agreement involving debt financing and a corporate governance amendment regarding authorized share capital.
Key Financial Metrics and Capital Structure
- Debt Financing: The Company entered into a Promissory Note with Nant Capital, LLC for a principal amount of $300,000,000.
- Proceeds: Gross proceeds received were $300,000,000.
- Interest Rate: Term Secured Overnight Financing Rate (SOFR) plus 5.4%.
- Maturity Date: December 17, 2022.
- Origination Fee: 0.5%.
- Conversion Option: In the event of default, the Company may convert outstanding principal and interest into common stock at a conversion price of $5.67 per share.
- Revenue and Profit: The filing text does not provide a clear value for revenue, profit, cash flow, or operating margins.
Material Changes and Corporate Actions
- Debt Obligation: Creation of a direct financial obligation of $300 million, maturing in one year.
- Authorized Shares: The Board approved an amendment to increase authorized Common Stock to 900,000,000 shares. This was approved by stockholders holding approximately 79% of issued shares on December 19, 2021, and will become effective 21 days after the mailing of the Information Statement.
- ATM Offering Status: The Company plans to pause its At-The-Market (ATM) equity offering for the near foreseeable future due to the receipt of the $300 million debt proceeds, though it reserves the right to resume at any time.
Guidance, Outlook, and Risks
- Management Commentary: The financing is intended to support ongoing operations. The Company issued a press release on December 20, 2021, regarding business initiatives and a year-in-review.
- Forward-Looking Statements: The report contains statements regarding the pause of the ATM offering and future capital needs. These are subject to market conditions and uncertainties.
- Risks: The Company notes that actual results may differ materially from forward-looking statements. The utilization of the ATM facility depends on future market conditions.
Investor Verification Checklist
- Verify the full terms of the Promissory Note attached as Exhibit 10.1, specifically regarding covenants and default triggers.
- Confirm the effective date of the authorized share increase (21 days post-mailing of the Information Statement).
- Monitor the Company's cash burn rate to assess the sufficiency of the $300 million proceeds through the December 2022 maturity date.
- Review the press release (Exhibit 99.1) for specific details on business initiatives and the "year in review" not fully detailed in this 8-K.